KRAS and non-small cell lung carcinoma: The aim of the current retrospective cohort study was the investigation of the role of KRAS mutational status as predictive biomarker on overall survival (OS) and its relation to PDL1 expression and other clinical characteristics of patients diagnosed with advanced NSCLC after receiving immunotherapy with or without platinum-based chemotherapy.